论文部分内容阅读
目的：探讨血清白细胞介素８（ＩＬ－８）变化在白血病中的意义。方法：采用夹心酶联免疫吸附法测定了 １０例急性淋巴细胞白血病（ＡＬＬ），２５例急性非淋巴细胞白血病（ＡＮＬＬ），１１例慢性粒细胞白血病（ＣＭＬ）慢性期血清ＩＬ－８浓度。结果：ＡＬＬ＼ＡＮＬＬ和ＣＭＬ患者血清ＩＬ－８水平显著高于正常对照组（Ｐ＜０．０１），ＡＬＬ与ＡＮＬＬ患者无显著性差异（Ｐ＞０．０５），急性单核细胞白血病组水平显著高于急性粒细胞白血病（ Ｍ１～Ｍ３）组（Ｐ＜０．０５），治疗有效的ＣＭＬ患者，治疗后ＩＬ－８水平显著低于治疗前水平（Ｐ＜０．０５）。结论：ＩＬ－８的变化可作为ＡＮＬＬ分型及监测ＣＭＬ治疗反应的一种手段。
Objective: To investigate the significance of serum interleukin-8 (IL-8) changes in leukemia. METHODS: Serum IL-8 levels in 10 patients with acute lymphoblastic leukemia (ALL), 25 patients with acute nonlymphocytic leukemia (ANLL), and 11 chronic myelogenous leukemia (CML) chronic phase were determined by sandwich enzyme-linked immunosorbent assay. Results: Serum IL-8 levels in patients with ALL/ANLL and CML were significantly higher than those in normal controls (P<0.01). There was no significant difference between patients with ALL and ANLL (P>0.05). Levels of IL-8 in patients with acute monocytic leukemia Significantly higher than the acute myelocytic leukemia (M1~M3) group (P<0.05). In patients with effective CML, the IL-8 level after treatment was significantly lower than before treatment (P<0.05). Conclusion: Changes in IL-8 can be used as a means of ANLL classification and monitoring of CML treatment response.